Jefferies initiated coverage of Tourmaline Bio with a Buy rating and $41 price target. Tourmaline is a clinical stage biotech company developing IL-6 treatment for thyroid eye disease and beyond, the analyst tells investors in a research note. The firm says IL-6 has shown efficacy in retrospective and observational studies in TED, and that the company’s lead asset TOUR006 is a potential best-in-class antibody.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TRML:
- Tourmaline Bio added to the NASDAQ Biotechnology Index
- Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
- Tourmaline Bio appoints Clay Siegall as chairman of the board
- Tourmaline Bio assumed with a Buy at H.C. Wainwright
- Tourmaline Bio initiated with a Buy at Truist
Questions or Comments about the article? Write to editor@tipranks.com